Lecanemab shows results in real-life dementia care, with brain swelling rare

If memory slips have been on your mind, here is encouraging news about dementia care. A real-world study of 181 people with Alzheimer’s disease found that the drug lecanemab worked in everyday clinics, and the brain swelling it can cause on scans was uncommon and produced no symptoms.

The best results showed up in the earliest stages of the disease. That is a good reason to act early if you or someone you love notices changes.

How the study worked

At several medical centers in Jiangsu, China, 181 people with Alzheimer’s received lecanemab every two weeks, and researchers checked how each person was doing at 3, 6 and 12 months using a standard dementia rating scale, published in October 2026 in Alzheimer’s & Dementia. There was no comparison group, so the study shows what happens in daily care rather than a head-to-head test against no treatment.

What they found

Lecanemab is an antibody given by IV. It clears amyloid, a sticky protein that builds up in the brain in Alzheimer’s disease. Here is how the people in the study did:

• Results arrived by month 6. A meaningful cognitive response appeared at 6 months and grew stronger by 12 months.
• Early stages did best. The response was mostly in people with mild cognitive impairment or mild dementia due to Alzheimer’s.
• Blood tests moved first. Two blood markers, p-tau217 and the amyloid ratio Aβ42/40, changed as early as month 3, before the clinical improvement showed.
• Brain swelling was rare. Swelling or small bleeds seen on MRI, called ARIA, occurred in 7.2% of people, and every case was without symptoms.

The authors conclude that lecanemab is effective and safe in Alzheimer’s over 6 to 12 months.

People who carry a gene variant called APOE ε4, and people with more severe cognitive impairment, were less likely to show a response. Which is one more reason timing matters.

Why does catching it early matter so much?

The drug works on a process that starts building up in the brain before dementia is advanced. In this study, the people who responded were mostly the ones treated while symptoms were still mild.

The blood markers are a useful bonus. Because p-tau217 and Aβ42/40 shifted by month 3, the authors describe them as practical, scalable signals that treatment has started to work, months before memory and thinking scores change.

What you can do today

If you have noticed memory changes in yourself or a relative, start a short list. Write down three concrete examples, such as a missed appointment, a repeated question or a familiar route that felt confusing. Bring the list to your next doctor’s visit. Specific examples help the doctor decide on the next steps, and the earlier that conversation happens, the more options there are.